Sundry Photography / Shutterstock.com
Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board (PTAB) that it should not institute inter partes reviews (IPRs) of a patent covering Actemra (Atlizumab), a treatment for arthritis under the NHK/Fintiv rule.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PTAB, Roche, patent , IPR, Fintiv, Actermra